Hodgkin lymphoma survival statistics

Survival

Survive Hodgkin lymphoma for 10 or more years, 2013-2017, England

Age

Age that Hodgkin lymphoma survival is highest, 2009-2013, England

 

Improvement

Hodgkin lymphoma survival in the UK has increased in the last 40 years

 

90.0% of males survive Hodgkin lymphoma for at least one year. This falls to 81.4% surviving for five years or more, as shown by age-standardised net survival for patients diagnosed with Hodgkin lymphoma during 2013-2017 in England.[1] Survival for females at one year is 91.4% and falls to 83.2% surviving for at least five years. Survival for females is similar to than for males at one year, and similar to at five years.

Hodgkin Lymphoma Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-99), England, 2013-2017

The bar chart shows one- and five-year net survival and predicted ten-year net survival, with 95% confidence intervals. Open a glossary item
 

Hodgkin lymphoma survival continues to fall beyond five years after diagnosis. 75.0% of people are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with Hodgkin lymphoma during 2013-2017 in England.[1]

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.

About this data

Data is for England, 2013 - 2017, ICD-10 C81.

Survival statistics give an overall picture of survival and the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year survival for Hodgkin lymphoma is highest in the youngest men and women and decreases with increasing age. Five-year net survival in men ranges from 95% in 15-39 year-olds to 23% in 80-99 year-olds for patients diagnosed with Hodgkin lymphoma in England during 2009-2013.[1] In women, five-year survival ranges from 94% to 33% in the same age groups.

Hodgkin Lymphoma (C81), Five-Year Net Survival by Age, England, 2009-2013

Last reviewed:

As with most cancers, survival for Hodgkin lymphoma is improving. Some of the increase is likely to be attributable to changes in the diagnosis, classification and registration of Hodgkin lymphoma, so interpretation of these trends should be undertaken with caution.

One-year age-standardised Open a glossary item net survival for Hodgkin lymphoma in men has increased from 74% during 1971-1972 to 91% during 2010-2011 in England and Wales – an absolute survival difference Open a glossary item of 17 percentage points.[1] In women, one-year survival has increased from 77% to 92% over the same time period (a difference of 15 percentage points).

Hodgkin Lymphoma (C81), Age-Standardised One-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five- and ten-year survival has increased by an even greater amount than one-year survival since the early 1970s. Five-year age-standardised net survival for Hodgkin lymphoma in men has increased from 54% during 1971-1972 to a predicted survival of 84% during 2010-2011 in England and Wales – an absolute survival difference of 30 percentage points.[1] In women, five-year survival has increased from 59% to 86% over the same time period (a difference of 27 percentage points).

Hodgkin Lymphoma (C81), Age-Standardised Five-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year survival for 2010-2011 is predicted using an excess hazard statistical model

Ten-year age-standardised net survival for Hodgkin lymphoma in men has increased from 45% during 1971-1972 to a predicted survival of 79% during 2010-2011 in England and Wales – an absolute survival difference of 34 percentage points.[1] In women, ten-year survival has increased from 51% to 83% over the same time period (a difference of 32 percentage points). Overall, 8 in 10 people diagnosed with Hodgkin lymphoma today are predicted to survive their disease for at least ten years.

Hodgkin Lymphoma (C81), Age-Standardised Ten-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Ten-year survival for 2005-2006 and 2010-2011 is predicted using an excess hazard statistical model

References

  1. Data were provided by London School of Hygiene and Tropical Medicine on request, 2014.

About this data

Data is for: England and Wales, 1971-2011, ICD-10 C81

Last reviewed:

Survival for Hodgkin lymphoma is strongly related to stage of the disease at diagnosis.

One-year net survival by stage 

One-year net survival for Hodgkin lymphoma is highest for patients diagnosed at Stage 1, and lowest for those diagnosed at Stage 4, as 2013-2017 data for England show.[1] 97% of patients diagnosed at Stage 1 survived their disease for at least one year, compared to 87% of patients diagnosed at Stage 4.[1]

One year net survival for unknown or missing stage is 84%. Lack of staging information may in some cases reflect advanced stage at diagnosis as very unwell patients may not undergo staging tests if the invasiveness of the testing outweighs the potential benefit of obtaining stage information. Incomplete staging assessment may also be associated with socio-demographic and clinical characteristics of the patient [2]. Stage completeness for Hodgkin lymphoma was 90% in 2013-2017 [1].

For patients diagnosed at Stage 2 to 4 and Stage Unknown, one-year net survival is similar for males and females. There is limited data available to compare males and females at Stage 1. [1]

Hodgkin Lymphoma cancer one-year net survival by stage, with incidence by stage (all data: adults diagnosed 2013-2017, followed up to 2018)

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.
  2. Girolamo, C. et al, Characteristics of patients with missing information on stage: a population-based study of patients diagnosed with a colon, lung or breast cancer in England in 2013, BMC Cancer (2018) 18:492

About this data

Data is for: England, 2013 - 2017, ICD-10 C81.

Survival statistics give an overall picture of survival but the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year relative survival for Hodgkin lymphoma in men in England (78%) is similar to the average for Europe (80%). Wales (76%), Scotland (80%) and Northern Ireland (84%) are also similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in men ranges from 57% (Bulgaria) to 85% (Norway).[1

Five-year relative survival for Hodgkin lymphoma in women in England (80%) is below the average for Europe (82%). Wales (78%) and Scotland (82%) are similar to the European average.[1] No five-year survival data is available for Northern Ireland. Across the European countries for which data is available, five-year relative survival in women ranges from 65% (Bulgaria) to 89% (Slovenia).[1

Hodgkin lymphoma (C81), Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, Hodgkin lymphoma (International Classification of Diseases for Oncology [ICD-O-3] C81).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.